FBLN1 as A Potential Drug Target and Biomarker (G2192)

Target Name: FBLN1

NCBI ID: G2192

FBLN1

FBLN1 as A Potential Drug Target and Biomarker

FBLN1 (FBLN1_HUMAN) is a gene that encodes a protein known as FBLN1. FBLN1 is a protein that is expressed in various tissues of the body, including the brain, heart, and blood vessels. It is a member of the Integrin alpha-2 (IAAG) family, which is a group of transmembrane proteins that play important roles in cell-cell and cell-extracellular matrix interactions.

FBLN1 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is also been shown to be involved in several cellular processes that are important for normal development and function, including cell adhesion, migration, and angiogenesis.

Diseases associated with FBLN1

FBLN1 is involved in several diseases that have a significant impact on human health. One of the most well-known diseases associated with FBLN1 is cancer. FBLN1 has been shown to be involved in the development and progression of several types of cancer, including neuroblastoma, breast cancer, and colorectal cancer.

In neuroblastoma, FBLN1 has been shown to promote the growth and survival of neuroblastoma cells. It has also been shown to play a role in the development of brain tumors in both humans and animals.

In breast cancer, FBLN1 has been shown to contribute to the growth and survival of breast cancer cells. It has also been shown to be involved in the development of resistance to chemotherapy in breast cancer.

In colorectal cancer, FBLN1 has been shown to contribute to the growth and survival of colorectal cancer cells. It has also been shown to be involved in the development of colorectal cancer stem cells.

Other diseases associated with FBLN1 include neurodegenerative diseases and autoimmune disorders. FBLN1 has been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It has also been shown to be involved in the development of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis.

FBLN1 as a drug target

FBLN1 is a protein that has the potential to be a drug target due to its involvement in several diseases. As a drug target, FBLN1 can be targeted with small molecules or antibodies to inhibit its function. This can lead to the development of new treatments for these diseases.

One approach to targeting FBLN1 is to use small molecules that can inhibit its activity. For example, researchers have developed a small molecule called BHV-350 that can inhibit FBLN1's activity. BHV-350 has been shown to be effective in preclinical studies in treating neuroblastoma and other neurodegenerative diseases.

Another approach to targeting FBLN1 is to use antibodies that recognize and bind to its protein. For example, researchers have developed an antibody called A201 that can bind to FBLN1 and inhibit its activity. A201 has been shown to be effective in preclinical studies in treating neuroblastoma and other neurodegenerative diseases.

FBLN1 as a biomarker

FBLN1 has also been shown to be a potential biomarker for several diseases. As a biomarker, FBLN1 can be used to diagnose and monitor the progression of these diseases.

For example, researchers have shown that FBLN1 levels can be used as a biomarker for neuroblastoma. They have found that FBLN1 levels are often elevated in neuroblastoma cells, and that these levels can be used to

Protein Name: Fibulin 1

Functions: Incorporated into fibronectin-containing matrix fibers. May play a role in cell adhesion and migration along protein fibers within the extracellular matrix (ECM). Could be important for certain developmental processes and contribute to the supramolecular organization of ECM architecture, in particular to those of basement membranes. Has been implicated in a role in cellular transformation and tumor invasion, it appears to be a tumor suppressor. May play a role in haemostasis and thrombosis owing to its ability to bind fibrinogen and incorporate into clots. Could play a significant role in modulating the neurotrophic activities of APP, particularly soluble APP

The "FBLN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBLN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets